A pproximately half of patients with ST-segment-elevation myocardial infarction (STEMI) have angiographically significant multivessel disease and, in these patients, the European (2012) and US (2013) guideline recommendations have been that only the culprit artery should be treated acutely. In the setting of cardiogenic shock, the guidelines recommend treating any nonculprit arteries to achieve as complete a revascularization as possible. Both of these recommended strategies are based on level C evidence (observational studies and consensus opinion). In the past 4 years, there have been 3 new randomized trials that have contributed to the knowledge base in this area (Table) .
The PRAMI trial (Preventive Angioplasty in Myocardial Infarction) was a UK-based multicenter randomized trial of culprit only percutaneous coronary intervention (PCI) in comparison with immediate complete revascularization. On the recommendation of the data safety and monitoring board, recruitment to the PRAMI trial was halted in January 2013, after 465 patients had been randomly assigned. After an average of 2 years follow-up, the relative risk reduction in the primary end point of cardiovascular death, nonfatal myocardial infarction (MI), and refractory ischemia in patients randomly assigned to complete revascularization was 65% (P<0.001), more than double that estimated in the original power calculation. The between-group difference in the secondary end point of cardiovascular death and nonfatal MI remained statistically significant (P<0.001). 1 The CvLPRIT (Complete versus Lesion-only Primary PCI Trial) was another UKbased multicenter randomized trial comparing the same 2 strategies as in PRAMI. The observed relative risk reduction in the primary end points in patients randomly assigned to complete revascularization was 55% (P=0.009).
2 Like PRAMI, the beneficial treatment effect was seen early, and, although staging was allowed in CvL-PRIT, the majority of patients randomly assigned to complete revascularization had it performed during the index procedure and even the staged patients waited only a median of 1.5 days. The true treatment effect in CvLPRIT may have been underestimated because, unlike PRAMI, patients were randomly assigned after angiography but before successful culprit lesion PCI. This led to crossovers, with 11 patients (7%) randomly assigned to complete revascularization undergoing culprit-only PCI and 7 patients (5%) randomly assigned to culprit-only PCI undergoing complete revascularization.
The DANAMI-3 PRIMULTI (Third Danish Study of Optimal Acute Treatment of Patients with ST-Segment Elevation Myocardial Infarction -Primary PCI in Multivessel Disease) was a randomized trial conducted in 2 centers in Denmark and compared culprit-only PCI with complete revascularization in patients with STEMI and multivessel disease. In the complete revascularization arm, all the nonculprit PCI procedures were staged, but they were performed within the index admission. The 
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SUMMARY
These 3 trials provide sufficient grounds to support immediate complete revascularization as the new standard of care for patients with STEMI and multivessel disease who do not have left main coronary artery disease or cardiogenic shock, or in whom the only nonculprit lesion is a chronic total occlusion. Why, then, have the most recent European and US guidelines only given this treatment strategy a lukewarm class IIb recommendation? Even in my own center, where we do >700 primary PCI procedures per year, there is limited enthusiasm for immediate complete revascularization.
Resistance to Change
I frequently hear cardiologists saying that the outcomes in these trials do not reflect what they see in their daily practice. In other words, my anecdotal experience trumps the randomized trials results. This is not evidence-based medicine.
Undertreatment in the Culprit-Only Groups
I also frequently hear the criticism that the control groups in all 3 trials were undertreated. Cardiologists state that the patients randomly assigned to culprit-only PCI should all have undergone ischemia testing and then been revascularized if there was evidence of important reversible ischemia. It is true that the subsequent management of the patients in these trials did not include protocol-mandated ischemia testing, but their care was in the hands of experienced cardiologists who could and did manage these patients as they saw fit. Because none of these trials was fully blinded, the clinicians knew which patients had angiographically significant but untreated lesions, and if they felt there was a need for ischemia testing or further revascularization, then it was performed. In any event, this criticism is based on the assumption that at least 1 mechanism of benefit in these trials was relief of ischemia in the territory of nonculprit arteries. However, in a 200-patient substudy of CvLPRIT using cardiovascular MRI, there was no evidence of a difference in ischemic burden at follow-up. 4 This is an important observation, because it may also explain, in part, the results of DANAMI-3 PRIMULTI. In this trial, unlike PRAMI and CvLPRIT, fractional flow reserve decision making was used to select which nonculprit stenoses should be stented within the diameter stenosis range of 50% to 90%. This resulted in approximately one-third of lesions (31%) that would have been stented on standard angiographic criteria being left untreated because of fractional flow reserve values >0.80. It should be noted that this study failed to show any effect on mortality or nonfatal MI. However, if in fact a major mechanism of benefit is stabilization of nonculprit but nevertheless vulnerable plaques, then angiographic selection criteria (as used in PRAMI and CvLPRIT) may be superior to fractional flow reserve guidance in this setting (ongoing studies will hopefully clarify this point).
Staging
Many cardiologists are convinced of the need for complete revascularization in patients with STEMI and mul- 
Complex Lesions
The operators in these trials were all experienced interventional cardiologists. Nevertheless, as can be seen from the CONSORT charts, hundreds of patients were excluded on the basis that their nonculprit disease was not amenable to PCI, and I would go further and say that the safe and efficient practice of immediate complete revascularization requires that the nonculprit disease be amenable to noncomplex PCI.
Conclusions
Hundreds of patients consented to participate in these complex trials. To my mind, the results are clear and we owe it to these patients to adopt the strategy of immediate complete revascularization whenever we have a good result in the culprit artery, and it is technically and logistically feasible.
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